Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Atezolizumab + Capecitabine |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | triple-receptor negative breast cancer | no benefit | Atezolizumab + Capecitabine | Phase III | Actionable | In a Phase III trial (Impassion132), the addition of Tecentriq (atezolizumab) to Xeloda (capecitabine) or Paraplatin (carboplatin) plus Gemzar (gemcitabine) treatment did not improve efficacy in early relapsing, unresectable, advanced CD274 (PD-L1)-positive triple-negative breast cancer patients, with median overall survival of 12.1 vs. 11.2 mo (HR=0.93, p=0.59), median progression-free survival of 4.2 vs. 3.6 mo, and objective response rates of 40% (61/177) vs. 28% (45/177) (PMID: 38755096; NCT03371017). | 38755096 |
PubMed Id | Reference Title | Details |
---|---|---|
(38755096) | IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. | Full reference... |